Compare Biogen Inc (BIIB) vs SoFi Technologies Inc (SOFI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Biogen Inc vs SoFi Technologies Inc — how do they compare? Biogen Inc trades at $191.19 (market cap $28.34B), while SoFi Technologies Inc trades at $18.69 (market cap $23.79B). The key difference: Biogen Inc is the larger of the two by market cap, and Biogen Inc is trading nearer its 52-week high, SoFi Technologies Inc nearer its low. Which is the better fit depends on your goals.
| BIIB | SOFI | |
|---|---|---|
Market Cap | $28.34B | $23.79B |
Sector | Health | Financials |
52-Week High | $216.63 | $32.21 |
52-Week Low | $122.68 | $15.15 |
Enterprise Value | $30.62B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Biogen (BIIB) trades at $209.03, up 4.96% today, with a bullish technical signal and strong analyst support. Recent quarterly earnings have consistently beaten expectations, and the company maintains solid profitability with a 75.49% gross margin. Key developments include FDA approval for a subcutaneous starter dose of Leqembi and promising Phase 2 data for its Alzheimer's drug diranersen, driving positive sentiment.
The outlook is positive, with a consensus price target of $230.18 suggesting upside. Investment opportunities lie in Alzheimer's pipeline advancements, but risks include clinical trial outcomes and competitive pressures. Revenue stability and cost management support fundamentals, though regulatory hurdles remain a watchpoint.
SoFi trades at $18.13, down 3.46% today but up from its year-to-date low near $15. The stock is in a bullish technical trend with key support at $18 and resistance at $19. Fundamentally, revenue grew to $3.61B in 2025 with net income of $481.32M, though cash flow from operations remains negative. Recent news highlights AI acquisitions and ETF launches as growth catalysts.
The outlook is mixed: analyst consensus targets $22.43 (24% upside) with 33% buy ratings, but risks include persistent negative operating cash flow and high P/E of 40.29. Earnings beats in recent quarters support growth narrative, yet profitability sustainability and interest rate sensitivity are key investor concerns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Biogen Inc
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. Aduhelm was approved as the firm's first Alzheimer's disease therapy in June 2021.
Read more on BIIB →About SoFi Technologies Inc
SoFi is a financial services company that was founded in 2011 and is currently based in San Francisco. Initially known for its student loan refinancing business, the company has expanded its product offerings to include personal loans, credit cards, mortgages, investment accounts, banking services, and financial planning. The company intends to be a one-stop shop for its clients' finances and operates solely through its mobile app and website. Through its acquisition of Galileo in 2020 the company also offers payment and account services for debit cards and digital banking.
Read more on SOFI →
